Literature DB >> 20645278

Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV.

Terri B Hyde1, D Scott Schmid, Michael J Cannon.   

Abstract

Congenital CMV infection is caused by in utero mother-to-fetus transmission and is a leading cause of birth defects and developmental disabilities. The highest risk of disability is to children born to women who have a primary infection during pregnancy, which can be detected by measuring seroconversion. We reviewed studies that reported rates of CMV seroconversion in different populations. Among pregnant women, annual seroconversion rates typically ranged from 1 to 7% (summary annual rate = 2.3%, 95% CI = 2.1-2.4%). Healthcare workers, including those caring for infants and children, had seroconversion rates similar to pregnant women (summary annual rate = 2.3%, 95% CI = 1.9-2.9%). Among day-care providers, seroconversion rates ranged from 0 to 12.5% (summary annual rate = 8.5%, 95% CI = 6.1-11.6%). Parents whose child was not shedding CMV were much less likely to seroconvert (summary annual rate = 2.1%, 95% CI = 0.3-6.8%) than were parents who had a child shedding CMV (summary annual rate = 24%, 95% CI = 18-30%). Nevertheless, over the course of a year, most parents exposed to a CMV-shedding child do not become infected. Other groups with elevated risk included families with a CMV-shedding member, female minority adolescents and women attending sexually transmitted disease clinics. The relatively low rate of CMV seroconversion in most populations is encouraging for behavioural interventions and for vaccine strategies attempting to prevent infection during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20645278     DOI: 10.1002/rmv.659

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  78 in total

1.  Seroprevalence of cytomegalovirus among children 1 to 5 years of age in the United States from the National Health and Nutrition Examination Survey of 2011 to 2012.

Authors:  Tatiana M Lanzieri; Deanna Kruszon-Moran; Minal M Amin; Stephanie R Bialek; Michael J Cannon; Margaret D Carroll; Sheila C Dollard
Journal:  Clin Vaccine Immunol       Date:  2014-12-17

2.  Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults.

Authors:  Julie H Ishida; Tracy Burgess; Michael A Derby; Pearline A Brown; Mauricio Maia; Rong Deng; Brinda Emu; Becket Feierbach; Ashley E Fouts; X Charlene Liao; Jorge A Tavel
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

3.  The risk of cytomegalovirus infection in daycare workers: a systematic review and meta-analysis.

Authors:  Karla Romero Starke; Marlen Kofahl; Alice Freiberg; Melanie Schubert; Mascha Luisa Groß; Stefanie Schmauder; Janice Hegewald; Daniel Kämpf; Johanna Stranzinger; Albert Nienhaus; Andreas Seidler
Journal:  Int Arch Occup Environ Health       Date:  2019-07-29       Impact factor: 3.015

4.  Natural History of Congenital Cytomegalovirus Infection in Highly Seropositive Populations.

Authors:  Marisa Marcia Mussi-Pinhata; Aparecida Yulie Yamamoto
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

5.  Human Cytomegalovirus Infection in Women With Preexisting Immunity: Sources of Infection and Mechanisms of Infection in the Presence of Antiviral Immunity.

Authors:  William J Britt
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

6.  Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.

Authors:  Cody S Nelson; Ilona Baraniak; Daniele Lilleri; Matthew B Reeves; Paul D Griffiths; Sallie R Permar
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

Review 7.  Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection.

Authors:  Michael J Cannon; Terri B Hyde; D Scott Schmid
Journal:  Rev Med Virol       Date:  2011-06-15       Impact factor: 6.989

8.  Influence of parity and sexual history on cytomegalovirus seroprevalence among women aged 20-49 years in the USA.

Authors:  Tatiana M Lanzieri; Deanna Kruszon-Moran; Manoj Gambhir; Stephanie R Bialek
Journal:  Int J Gynaecol Obstet       Date:  2016-06-29       Impact factor: 3.561

Review 9.  Controversies in the natural history of congenital human cytomegalovirus infection: the paradox of infection and disease in offspring of women with immunity prior to pregnancy.

Authors:  William Britt
Journal:  Med Microbiol Immunol       Date:  2015-03-13       Impact factor: 3.402

Review 10.  Congenital cytomegalovirus infection: new prospects for prevention and therapy.

Authors:  Elizabeth C Swanson; Mark R Schleiss
Journal:  Pediatr Clin North Am       Date:  2013-04       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.